Medulloblastomics

The end of the beginning

Paul A. Northcott, David T.W. Jones, Marcel Kool, Giles W. Robinson, Richard J. Gilbertson, Yoon-Jae Cho, Scott L. Pomeroy, Andrey Korshunov, Peter Lichter, Michael D. Taylor, Stefan M. Pfister

Research output: Contribution to journalReview article

339 Citations (Scopus)

Abstract

The division of medulloblastoma into different subgroups by microarray expression profiling has dramatically changed our perspective of this malignant childhood brain tumour. Now, the availability of next-generation sequencing and complementary high-density genomic technologies has unmasked novel driver mutations in each medulloblastoma subgroup. The implications of these findings for the management of patients are readily apparent, pinpointing previously unappreciated diagnostic and therapeutic targets. In this Review, we summarize the 'explosion' of data emerging from the application of modern genomics to medulloblastoma, and in particular the recurrent targets of mutation in medulloblastoma subgroups. These data are currently making their way into clinical trials as we seek to integrate conventional and molecularly targeted therapies.

Original languageEnglish (US)
Pages (from-to)818-834
Number of pages17
JournalNature Reviews Cancer
Volume12
Issue number12
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Medulloblastoma
Mutation
Explosions
Genomics
Brain Neoplasms
Clinical Trials
Technology
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y-J., ... Pfister, S. M. (2012). Medulloblastomics: The end of the beginning. Nature Reviews Cancer, 12(12), 818-834. https://doi.org/10.1038/nrc3410

Medulloblastomics : The end of the beginning. / Northcott, Paul A.; Jones, David T.W.; Kool, Marcel; Robinson, Giles W.; Gilbertson, Richard J.; Cho, Yoon-Jae; Pomeroy, Scott L.; Korshunov, Andrey; Lichter, Peter; Taylor, Michael D.; Pfister, Stefan M.

In: Nature Reviews Cancer, Vol. 12, No. 12, 01.12.2012, p. 818-834.

Research output: Contribution to journalReview article

Northcott, PA, Jones, DTW, Kool, M, Robinson, GW, Gilbertson, RJ, Cho, Y-J, Pomeroy, SL, Korshunov, A, Lichter, P, Taylor, MD & Pfister, SM 2012, 'Medulloblastomics: The end of the beginning', Nature Reviews Cancer, vol. 12, no. 12, pp. 818-834. https://doi.org/10.1038/nrc3410
Northcott PA, Jones DTW, Kool M, Robinson GW, Gilbertson RJ, Cho Y-J et al. Medulloblastomics: The end of the beginning. Nature Reviews Cancer. 2012 Dec 1;12(12):818-834. https://doi.org/10.1038/nrc3410
Northcott, Paul A. ; Jones, David T.W. ; Kool, Marcel ; Robinson, Giles W. ; Gilbertson, Richard J. ; Cho, Yoon-Jae ; Pomeroy, Scott L. ; Korshunov, Andrey ; Lichter, Peter ; Taylor, Michael D. ; Pfister, Stefan M. / Medulloblastomics : The end of the beginning. In: Nature Reviews Cancer. 2012 ; Vol. 12, No. 12. pp. 818-834.
@article{b3c595d2f7ee4d0fa36d34d7b355a5f9,
title = "Medulloblastomics: The end of the beginning",
abstract = "The division of medulloblastoma into different subgroups by microarray expression profiling has dramatically changed our perspective of this malignant childhood brain tumour. Now, the availability of next-generation sequencing and complementary high-density genomic technologies has unmasked novel driver mutations in each medulloblastoma subgroup. The implications of these findings for the management of patients are readily apparent, pinpointing previously unappreciated diagnostic and therapeutic targets. In this Review, we summarize the 'explosion' of data emerging from the application of modern genomics to medulloblastoma, and in particular the recurrent targets of mutation in medulloblastoma subgroups. These data are currently making their way into clinical trials as we seek to integrate conventional and molecularly targeted therapies.",
author = "Northcott, {Paul A.} and Jones, {David T.W.} and Marcel Kool and Robinson, {Giles W.} and Gilbertson, {Richard J.} and Yoon-Jae Cho and Pomeroy, {Scott L.} and Andrey Korshunov and Peter Lichter and Taylor, {Michael D.} and Pfister, {Stefan M.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1038/nrc3410",
language = "English (US)",
volume = "12",
pages = "818--834",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Medulloblastomics

T2 - The end of the beginning

AU - Northcott, Paul A.

AU - Jones, David T.W.

AU - Kool, Marcel

AU - Robinson, Giles W.

AU - Gilbertson, Richard J.

AU - Cho, Yoon-Jae

AU - Pomeroy, Scott L.

AU - Korshunov, Andrey

AU - Lichter, Peter

AU - Taylor, Michael D.

AU - Pfister, Stefan M.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - The division of medulloblastoma into different subgroups by microarray expression profiling has dramatically changed our perspective of this malignant childhood brain tumour. Now, the availability of next-generation sequencing and complementary high-density genomic technologies has unmasked novel driver mutations in each medulloblastoma subgroup. The implications of these findings for the management of patients are readily apparent, pinpointing previously unappreciated diagnostic and therapeutic targets. In this Review, we summarize the 'explosion' of data emerging from the application of modern genomics to medulloblastoma, and in particular the recurrent targets of mutation in medulloblastoma subgroups. These data are currently making their way into clinical trials as we seek to integrate conventional and molecularly targeted therapies.

AB - The division of medulloblastoma into different subgroups by microarray expression profiling has dramatically changed our perspective of this malignant childhood brain tumour. Now, the availability of next-generation sequencing and complementary high-density genomic technologies has unmasked novel driver mutations in each medulloblastoma subgroup. The implications of these findings for the management of patients are readily apparent, pinpointing previously unappreciated diagnostic and therapeutic targets. In this Review, we summarize the 'explosion' of data emerging from the application of modern genomics to medulloblastoma, and in particular the recurrent targets of mutation in medulloblastoma subgroups. These data are currently making their way into clinical trials as we seek to integrate conventional and molecularly targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=84870215426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870215426&partnerID=8YFLogxK

U2 - 10.1038/nrc3410

DO - 10.1038/nrc3410

M3 - Review article

VL - 12

SP - 818

EP - 834

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 12

ER -